The androgen receptor axis is crucial in prostate cancer pathology by driving tumor proliferation and growth.3,4 While androgen-deprivation therapy (ADT), which reduces circulating testosterone levels, has been the cornerstone of treatment, single-agent ADT alone often fails to sustain long-term efficacy, as prostate cancer cells develop adaptive resistance to testosterone suppression. Here, AR is linked to neoplasm.